

CURRICULUM VITAE

Personal Data

Francesca Paola Giunta, born in Ivrea, Torino Italy on 23/09/1974
Address: Via Bardassano 7, 10132 Torino Italy
Phone: 0039-338-6656216
Nationality: Italian, British.

Studies

15/04/2002: Degree in Medicine at Turin University.
13/12/2006: Post-graduation specialisation in Nuclear Medicine at Turin University

Workplaces

08/02/2007-01/04/2007: participation in the clinical audit designed by the regional CPO for Piedmont, in association with the Emilia Romagna region, for the definition of the 2007 Guidelines for the use of 18F-FDG PET-CT in oncology.

07/05/2007- 06/11/2009: working at the Nuclear Medicine Department at Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

15/02/2010-31/03/2014: working at Turin University Hospital (Città della Salute e della Scienza di Torino), Nuclear Medicine Department.

01/04/2014-16/07/2017: working at the Nuclear Medicine Department of Ivrea Hospital, Italy.

Since 17/07/2017: back at Turin University Hospital (Città della Salute e della Scienza di Torino), Nuclear Medicine Department.

Participation since 2014 in the Imaging Group (for Nuclear Medicine) at the 2nd level post-specialization University Master: "Pathways in Gynecological Oncology".

Scientific production

Abstracts:

- FDG PET/CT for evaluation of treatment response of primary lung cancer after stereotactic radiotherapy. E.Pelosi, M.Racca, U.Ricardi, A.Guarneri, T.Spandonari, M.Pennone, C.Fiandra, F.Giunta, R.Ragona, G.Bisi.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 50-Suppl.1 to issue No.4 pag. 71

- ^{18}F -FDG-PET positive predictive value in the detection of bone marrow disease in patients with malignant lymphoma. D.Penna, F.Giunta, D.Deandreis, A.Chiappella, P.Pregno, A.Dourokas, T.Varetto, U.Vitolo, E.Pelosi, G.Bisi.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 50-Suppl.1 to issue No.4 pag. 85.
- Does the semiquantitative parameter SUVmax have significance as an outcome predictor in patients with newly-diagnosed advanced NSCLC? F.Giunta, S.Novello, V.Arena, G.Selvaggi, A.Dourokas, A.Skanjeti, A.Billè, M.Giaj Levra, M.Longo, G.V. Scagliotti, E.Pelosi
Poster al II IASLC INTERNATIONAL WORKSHOP; Torino 24-26 Settembre 2006
Abstract book pag. 53.
Poster.
- Influence of ^{68}Ga -DOTATOC PET-CT in the first-line work-up and therapeutic management of patients with neuroendocrine tumours. F.Giunta, A.Filice, A.Fraternali, A.Versari, M.Di Paolo, E.Calandri, D.Salvo.
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 2): S127-S153.
Comunicazione orale.
- ^{68}Ga -DOTATOC PET-CT in neuroendocrine tumours: comparison with endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration. A.Versari, L.Camellini, A.Fraternali, M.Asti, G.Carlinfante, A.Frasoldati, F.Giunta, F.Fioroni, F.Azzolini, R.Sassatelli, D.Salvo.
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 2): S127-S153.
Comunicazione orale.
- ^{68}Ga -DOTATOC PET-CT and ^{90}Y -DOTATOC therapy: perspectives in patients with metastatic differentiated thyroid cancer negative at radioiodine scan. F.Giunta, A.Filice, A.Versari, A.Fraternali, A.Frasoldati, N.Cremonini, M.Asti, E.Grassi, D.Salvo.
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 2): S127-S153.
Comunicazione orale.
- ^{90}Y -DOTATOC in the treatment of metastatic neuroendocrine tumours: preliminary results. A.Filice, F.Giunta, A.Fraternali, A.Versari, A. Frasoldati, A.Carpi, M.Di Paolo, M.Asti, F.Fioroni D.Salvo.
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 2): S181-S198.
Comunicazione orale.
- Influenza del ^{68}Ga DOTATOC PET-CT nelle scelte terapeutiche in pazienti affetti da tumore neuroendocrino. F.Giunta, A.Fraternali, A.Filice, M. Di Paolo, A.Versari, D.Salvo.
La Radiologia Medica, Suppl Vol.113, Maggio 2008.
Comunicazione orale 43esimo Congresso SIRM. 24/05/2008, Roma.

- DOTATOC in PET-CT diagnostics and metabolic therapy in patients with advanced differentiated thyroid cancer negative at radioiodine scan. A.Fraternali, A.Filice, A.Versari, A.Frasoldati, F.Giunta, N.Cremonini, M.Asti, F.Fioroni, M. Di Paolo, E.Calandri, D.Salvo.
Quarterly Journal of Nuclear Medicine and Molecular Imaging Vol. 53 Suppl.1 to issue n. 2 pag. 80.
- ⁹⁰Y-DOTATOC in the treatment of patients with metastatic neuroendocrine tumours. A.Fraternali, A.Versari, A.Frasoldati, A.Carpi, M.Asti, A.Filice, M.Di Paolo, E.Grassi, F.Giunta, E.Calandri, D.Salvo.
Quarterly Journal of Nuclear Medicine and Molecular Imaging Vol. 53 Suppl.1 to issue n. 2 pag. 151.
- Large vessel vasculitis pattern in patients with chronic periaortitis: role of FDG-PET. A.Versari, A.Vaglio, A.Palmisano, N.Pipitone, F.Giunta, C.Buzio, C.Salvarani, D.Salvo.
Quarterly Journal of Nuclear Medicine and Molecular Imaging Vol. 53 Suppl.1 to issue n. 2 pag. 182.
- Sentinel node scintigraphy in breast cancer: our experience with deep peritumoral injection. A.Versari, M.Di Paolo, C.A.Mori, C.Pedrazzoli, A.Fraternali, A.Filice, F.Giunta, E.Calandri, D.Salvo.
Quarterly Journal of Nuclear Medicine and Molecular Imaging Vol. 53 Suppl.1 to issue n. 2 pag. 192.
- Large vessel inflammatory pattern in chronic periaortitis: the role of FDG-PET. E.Calandri, F.Giunta, A.Vaglio, A.Palmisano, N.Pipitone, C.Buzio, C.Salvarani, A.Versari, D.Salvo.
Eur J Nucl Med Mol Imaging (2009) 36 (Suppl.2): S281-S496.
Comunicazione orale.
- Sentinel node biopsy in early stage breast cancer: how deep radiocolloid peritumoral injection can change the patient management. F.Giunta, E.Calandri, M.Di Paolo, C. Mori, C.Pedrazzoli, A.Fraternali, A.Filice, A.Versari, D.Salvo.Eur J Nucl Med Mol Imaging (2009) 36 (Suppl.2): S194-S233.Comunicazione orale.
- Interim 18-FDG-PET/CT does not predict the outcome of patients with Diffuse Large B-Cell Lymphoma (DLBCL) treated with R-CHOP. M.Bellò, F.Giunta, P.Pregno, M.Ladetto, M.Menga, R.Passera, F.Salvi, S.Franceschetti, L.Rigacci, U.Vitolo, G.Bisi. Eur J Nucl Med Mol Imaging (2010) 37 (Suppl 2):S198-S311
- ⁹⁰Y-Ibritumomab-Tiuxetan is useful as consolidation of first-line therapy of follicular and indolent non follicular lymphomas and in combination with high dose

chemotherapy regimens. M.Bellò, F.Giunta, B.Botto, A.Parente, C.Ciochetto, U.Vitolo, G.Bisi. Eur J Nucl Med Mol Imaging (2010) 37 (Suppl 2):S312-S332

- Appropriatelyzza dell'uso della tomografia ad emissione di positroni in oncologia: uno studio regionale di audit. Monagheddu C, Galassi C, Biggi A, Bisi G, Inglese E, Mancini M, Contu V, Giunta F, Marra A, Ballini L, Liberati A, Bertetto O, Ciccone G. Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte (CPO): Schede e programma di attività 2011, relazione di attività 2010, elenco pubblicazioni 2010, pag.249.
- Cardiac FDG uptake increases after ABVD (Adriamycine, Bleomycine, Vincristine, Dacarbazine) and support therapy with steroids and G-CSF: an observation on 24 patients with newly-diagnosed Hodgkin's Disease. A.Parente, M.Finessi, D.Nicolotti, F.Giunta, M.Bellò, R.Passera, P.Pregno, S.Ferrero, M.Ladetto, G.Bisi. Eur J Nucl Med Mol Imaging (2012) 39 (Suppl 2):S384-S497
- 18F-FDG-PET-CT evaluation of response to chemoimmunotherapy of primary mediastinal large B-cell lymphoma (PLMBCL): comparison in the performance of different reporting criteria. F. Giunta, M. Zotta, M. Menga, A.R. Filippi, A. Douroukas, M. Balma, M. Bellò, U. Ricardi, G. Bisi. Clin Transl Imaging (2013) 1 (Suppl 1):S1-S38
- Cardiac FDG uptake increases after chemotherapy and support therapy with steroids and granulocyte-colony stimulating factors: an observation on 24 patients with newly-diagnosed Hodgkin's Disease. M.Finessi, A.Parente, D.Nicolotti, F.Giunta, M.Bellò, R.Passera, P.Pregno, S.Ferrero, M.Ladetto, G.Bisi. Clin Transl Imaging (2013) 1 (Suppl 1):S39-S140
- 18F-FDG PET/CT evaluation of response to chemoimmunotherapy of primary mediastinal large B-cell lymphoma (PMBCL): comparison of the performance of different reporting criteria. F Giunta, M Zotta, M Menga, AR Filippi, A Douroukas, M Balma, M Bellò, U Ricardi G Bisi. Clin Transl Imaging (2013) 1 (Suppl 1):S1-S38

Publications:

- Feasibility of the sentinel node biopsy in anal cancer. M.Mistrangelo, M.Bellò, A.Mobiglia, G.Beltramo, P.Cassoni, E.Milanesi, S.Cornaglia, E.Pelosi, F.Giunta, S.Sandrucci, A.Mussa. Q J Nucl Med Mol Imaging 2009; 53:3-8.
- La tomografia ad emissione di positroni con ¹⁸F-Fluorodesossiglucosio (¹⁸F-FDG-PET): nuovi criteri per un uso appropriato. A.Filice, F.Giunta, A.Fraternali, M.Di Paolo, A.Versari, D.Salvo. Lo Spallanzani (2007): 21: 59-68.

- Ga-68 DOTATOC PET, endoscopic ultrasonography and multidetector CT in the diagnosis of duodeno-pancreatic neuroendocrine tumors: a single-centre retrospective study. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R. Clin Nucl Med. 2010 May;35(5):321-8.
- The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP. P.Pregno, A.Chiappella, M.Bellò, B.Botto, S.Ferrero, S.Franceschetti, F.Giunta, M.Ladetto, G.Limerutti, M.Menga, M.Nicolosi, G.Priolo, B.Puccini, L.Rigacci, F.Salvi, L.Vaggelli, R.Passera, G.Bisi and U.Vitolo. Blood, 1 March 2012, Vol. 119, n.9, p. 2066-2073.
- Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona M, Vitolo U, Bisi G, Ricardi U. Int J Radiation Oncol Biol Phys 2013, 87 (2):311-16
- Using PET-CT in the Restaging of Primitive Mediastinal B-Cell Lymphoma (PMBCL) after chemotherapy: which criteria should we use? Giunta F, Zotta M, Menga M, Balma M, Bellò M, Passera R, Filippi AR, Chiappella A, Ladetto M, Ricardi U, Vitolo U, Bisi G. Q J Nucl Med Mol Imaging 2015 Jun; 59(2):214-9.
- Interventional locoregional treatment and metabolic response: advantages of using PET/CT in the evaluation of response to treatment. Finessi M., Bellò M., Giunta F., Veltri A., Deanderies D. QJNucl Med Mol Imaging. 2017 Nov 22 do: 10.237367s1824-4785.17.03037-0 Epub ahead of print

Areas of particular interest:

Use of 18FDG-PET/CT in the assessment of response to therapy in Lymphomas;
 Use of 18FDG-PET/CT in the gynecologic oncology;
 Radioembolisation